The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to a promising new treatment for dry age-related macular degeneration (AMD)—a leading cause of vision loss.
The therapy is being developed by Luxa Biotechnology and supported in part by the California Institute for Regenerative Medicine (CIRM).
What RMAT Designation Means
RMAT designation is given to regenerative medicine therapies that show strong early results in treating serious conditions like dry AMD. It allows the FDA to work more closely with developers to speed up clinical trials and the approval process, helping new treatments reach patients faster.
A New Approach to Treating Dry AMD
Dry AMD affects nearly 20 million people in the United States. It occurs when cells in the macula—the central part of the retina responsible for sharp vision—gradually break down, leading to vision loss.
Luxa’s therapy focuses on replacing damaged cells in the eye. Researchers grow retinal pigment epithelial (RPE) cells in the lab and transplant them into the retina to help restore function. These cells support photoreceptors, which are essential for detecting light and enabling vision.
Clinical Trial Progress
Dr. Jeffery Stern, Luxa’s Chief Medical Officer, leads the Phase 1/2a clinical trial. The trial is supported by a $4 million grant from CIRM, along with contributions from the National Eye Institute.
Dr. Stern will present data from the Phase 1 trial at the Wills Eye Conference in Philadelphia on March 6, 2025.
Early clinical data helped secure the RMAT designation. That data highlights the therapy’s potential to address an unmet need for patients with dry AMD. Currently treatment options for dry AMD are limited.
Why This Matters
If successful, this cell-based therapy could become a new regenerative medicine treatment for AMD. The progress offers some hope to millions at risk of vision loss. RMAT designation signals that the FDA sees strong potential in this approach and is prioritizing its development.
CIRM has invested more than $200 million in vision research, including multiple AMD therapy programs, reinforcing its commitment to advancing treatments for blindness and vision impairment.
“Luxa’s therapy shows potential in restoring lost vision in patients with dry AMD,” said Joseph Gold, PhD, Senior Director of Clinical Development at CIRM.
This is the first CIRM-funded clinical trial for dry AMD to receive RMAT designation.
Related Posts
Advancing cell therapy research for dry age-related macular degeneration
CIRM-funded study helps unlock some of the genetic secrets behind AMD
Stem cell stories that caught our eye: new CRISPR fix for sickle cell
Oh wow, great new, I wish this could help me regain my vision… I had an accident and damaged my left eye.. the doctor said it’s a scar on the retinal and nothing can’t done to regain my vision… I can only very blurry on the left eye.. my right eye is good, Thank God! 🙏